Lehman Repeats Buy on Decode Genetics
Decode Genetics (DCGN ) and its partner Roche announced identification of the stroke gene, and the location of the gene linked to Type 2 diabetes. Lehman Brothers reiterated its buy rating on shares of Decode.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.